Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Michał O. Zembala"'
Publikováno v:
International Journal of Cardiology. Cardiovascular Risk and Prevention, Vol 22, Iss , Pp 200297- (2024)
Lipoprotein(a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin are in clinical trials and have been shown to be effective in sig
Externí odkaz:
https://doaj.org/article/6c3d15e4affa451c9d73960592c73207
Autor:
Ewa Trejnowska, Dominik Drobiński, Piotr Knapik, Marta Wajda-Pokrontka, Konstanty Szułdrzyński, Jakub Staromłyński, Wojciech Nowak, Maciej Urlik, Marek Ochman, Waldemar Goździk, Wojciech Serednicki, Jakub Śmiechowicz, Jakub Brączkowski, Wojciech Bąkowski, Anna Kwinta, Michał O. Zembala, Piotr Suwalski
Publikováno v:
Critical Care, Vol 26, Iss 1, Pp 1-10 (2022)
Abstract Background In Poland, the clinical characteristics and outcomes of patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO) remain unknown. This study aimed to answer these unknowns by analyzing data collected from high-vo
Externí odkaz:
https://doaj.org/article/451db3434ceb403d9a55d71d758b6f51
Autor:
Grzegorz M. Kubiak, Radosław Kwieciński, Agnieszka Ciarka, Andrzej Tukiendorf, Piotr Przybyłowski, Tomasz Hrapkowicz, Michał O. Zembala
Publikováno v:
Cardiology Research and Practice, Vol 2020 (2020)
Introduction. The data assessing the impact of beta blocker (BB) medication on survival in patients after heart transplantation (HTx) are scarce and unequivocal; therefore, we investigated this population. Methods. We retrospectively analyzed the HTx
Externí odkaz:
https://doaj.org/article/fa1169ef121b4315b19d2ea02c7624a0
Autor:
Stanisław Surma, Michał O. Zembala
Publikováno v:
Choroby Serca i Naczyń. 19:160-177
Publikováno v:
Folia Cardiologica. 18:24-30
Publikováno v:
Choroby Serca i Naczyń. 19:131-143
Autor:
Ewa Trejnowska, Dominik Drobiński, Piotr Knapik, Marta Wajda-Pokrontka, Konstanty Szułdrzyński, Jakub Staromłyński, Wojciech Nowak, Maciej Urlik, Marek Ochman, Waldemar Goździk, Wojciech Serednicki, Jakub Śmiechowicz, Jakub Brączkowski, Wojciech Bąkowski, Anna Kwinta, Michał O. Zembala, Piotr Suwalski
Publikováno v:
Critical care (London, England). 26(1)
Background In Poland, the clinical characteristics and outcomes of patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO) remain unknown. This study aimed to answer these unknowns by analyzing data collected from high-volume ECMO
Autor:
Katarzyna Ratman, Agnieszka Biełka, Mariusz E Kalinowski, Mirosława M Herdyńska-Wąs, Piotr Przybyłowski, Michał O Zembala
Publikováno v:
Kardiologia Polska. 80:709-710
Autor:
Ewa Trejnowska, Szymon Skoczyński, Andrzej S Swinarew, Magda Tarczyńska – Słomian, Paul Armatowicz, Paweł Cyprys, Daniel Cieśla, Michał O Zembala, Piotr Knapik, Katarzyna Hryniewicz
Publikováno v:
Perfusion. :026765912211301
Introduction Lactate levels have been recognized as a reliable tool for monitoring critically ill patients requiring venoarterial extracorporeal membrane oxygenation (VA ECMO) or venovenous extracorporeal membrane oxygenation (VV ECMO) but the reason
Autor:
Marcin, Świerad, Krzysztof, Dyrbuś, Janusz, Szkodziński, Michał O, Zembala, Zbigniew, Kalarus, Mariusz, Gąsior
Publikováno v:
Polish archives of internal medicine. 130(7-8)